AFT licenses Maxigesic(R) IV in 21 new countries

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 5 February 2020

AFT licenses Maxigesic® IV in 21 new countries across CIS
and Central America
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces it has licensed its
Maxigesic® intravenous medicine (Maxigesic® IV) in 21 new countries across the
Commonwealth of Independent States (CIS) and Central America, territories with a
combined population of more than 220 million people.
The agreements, which follow the registration of Maxigesic® IV in Australia and New
Zealand in 2019, is part of AFT’s continuing drive to capitalise on the strong global
potential it sees for its patented Maxigesic pain-relief platform.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “These agreements
take to 90 the number of countries in which Maxigesic® IV is now licensed. They are
further evidence of the strong global appetite we have from partners around the
world to invest in the commercialisation of the Maxigesic platform.
“With the completion of these agreements AFT will commence work on regulatory
filings in these new territories using the current Australian Maxigesic® IV registration,
which is accepted as a reference country for many regions internationally, including
CIS and Central America,” Dr Atkinson said.
Dr Atkinson said the company was targeting sales of Maxigesic in these territories
commencing in late FY21 and the FY22 financial years.
COMMONWEALTH OF INDEPENDENT STATES
The new license covering CIS is with the Cyprus-based Medochemie, which already
holds a license for Maxigesic tablets in Cyprus (and is due to commence sales of the
dose form in that country later this year).
The new license for Maxigesic® IV in the CIS covers an area with a population base of
over 139 million
1
people and includes the Ukraine, Azerbaijan, Belarus, Kazakhstan,
Kyrgyzstan, Armenia, Moldova, Tajikistan, Uzbekistan and Turkmenistan.
CENTRAL AMERICA
AFT’s Central American licensing agreement with Germany’s Pharma Bavaria will
bring the Maxigesic® IV into the Central American Common Market (CACM).
It covers an area with a combined population of 84 million
2
, including Panama, Costa
Rica, El Salvador, Honduras, Nicaragua and Guatemala as well as other countries in

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

the Central American and Caribbean regions including Belize, the Dominican
Republic, Haiti, Trinidad & Tobago and Cuba.
Notes to editors:
Maxigesic® IV (Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) is an
intravenous formulation developed as a line extension to Maxigesic tablets, for use
post-operatively in hospitals where patients cannot take an oral medicine. A major
Phase 3 clinical trial conducted in Texas and Maryland USA found that Maxigesic IV
provided significantly better pain relief than either paracetamol (acetaminophen) IV
or ibuprofen IV alone in the same doses.
3

For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
.
About Medochemie
Medochemie is a Cyprus based multinational Pharmaceutical Company that
develops licenses, manufactures, markets, and distributes branded generic and
super-generic pharmaceutical products as well as its own patented brands. With a
wide product portfolio and a diverse multinational workforce, Medochemie is well
situated to bring the Maxigesic IV product line into the CIS region.

About Pharma Bavaria
Pharma Bavaria International Group operates in more than 45 countries. With a strong
focus on growth regions such as the Middle East, Africa, South-East Asia, CIS countries
and other emerging economies Pharma Bavaria’s portfolio of prescription medicines
includes anti-infectives, analgesic/anti-inflammatory, flu and cold, gastroenterology,
oncology, cardiology and women’s healthcare areas.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

References:
1
https://data.worldbank.org/indicator/SP.POP.TOTL?name_desc=true
2
https://www.worlddata.info/alliances/cacm-central-american-common-
market.php
3
Daniels SE et al. Efficacy and safety of an IV acetaminophen/ibuprofen
combination after bunionectomy. A randomized, double-blind, factorial,
placebo-controlled trial. Submitted for publication